AstraZeneca's (AZN) Tagrisso Hits Phase III Primary Endpoint
Zacks Investment Research | Jul 19, 2016 06:54AM ET
AstraZeneca plc (NYSE:AZN) announced that its lung cancer drug, Tagrisso, met the primary endpoint in a randomized phase III study (AURA3). The study evaluated the efficacy and safety of Tagrisso as a second-line treatment of patients suffering from EGFR T790M mutation-positive, locally-advanced or metastatic non-small cell lung cancer (NSCLC), whose disease had progressed following first-line EGFR tyrosine kinase inhibitor therapy.
Results showed that Tagrisso demonstrated superior progression-free survival (PFS) compared to standard platinum-based doublet chemotherapy with a safety profile that was found to be consistent with previous studies. In addition to PFS, the objective response rate, disease control rate and duration of response also achieved clinically meaningful improvement versus chemotherapy.
Meanwhile, full evaluation of AURA3 study data including an analysis of overall survival is currently ongoing and the company intends to present the data at an upcoming medical meeting.
We are encouraged by the phase III study results. We note that Tagrisso is currently approved in both the U.S. and EU for the treatment of patients with EGFR T790M mutation-positive advanced NSCLC. It is the first drug to be approved for this indication. Eligibility for treatment with Tagrisso is dependent on confirmation that the EGFR T790M mutation is present in the tumor.
Initial sales of the drug have been encouraging reflecting increased testing rates, which have been driving the number of new-patient starts.
Currently, Tagrisso is also being evaluated in the adjuvant and metastatic first-line settings, including patients with and without brain metastases, in leptomeningeal disease, and in combination with other treatments.
AstraZeneca is working on strengthening its oncology product portfolio and has several candidates in its pipeline. The company’s target is to launch at least six new medicines between 2014 and 2020.
AstraZeneca is a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the health care sector include Bristol-Myers Squibb Company (NYSE:BMY) , Innoviva, Inc. (NASDAQ:INVA) and Fibrocell Science, Inc. (NASDAQ:FCSC) . All three stocks sport a Zacks Rank #1 (Strong Buy).
Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.